Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00420342 · ClinicalTrials.gov registry record · Phase 2
Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
NCT00420342 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 92 participants.
The verdict
NCT00420342, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
Study Summary
The main purpose of this study is to compare the effects of treatment of two different formulations of Angeliq® and Prempro on blood pressure in post-menopausal women with prehypertension.
Interventions
- DRUG Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)
- DRUG SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2007-01 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00420342
The ClinicalTrials.gov registry entry for NCT00420342 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Drospirenone/17ß-estradiol (Angeliq, BAY86-4891) is the first listed.
NCT00420342 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00420342 about?
NCT00420342 is a clinical study titled "Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension". The main purpose of this study is to compare the effects of treatment of two different formulations of Angeliq® and Prempro on blood pressure in post-menopausal women with prehypertension.
What is the current status of trial NCT00420342?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2007-01. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00420342?
The interventions under investigation include: Drospirenone/17ß-estradiol (Angeliq, BAY86-4891) (DRUG), SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM) (DRUG).
Who is sponsoring clinical trial NCT00420342?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.